ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Research Article

Open Vet J. 2025; 15(5): 2182-2192


Mechanism of recombinant 1,3-β-glucanase as antibiofilm to prevent antimicrobial resistance in antifungal therapy for vulvovaginitis candidiasis

Masfufatun Masfufatun, Afaf Baktir, Rini Purbowati.



Abstract
Download PDF Cited by 0 ArticlesPost

Background:
Candida albicans is an opportunistic pathogen that can form biofilms, thereby increasing resistance to antifungals such as fluconazole. The extracellular matrix of biofilms rich in β-1,3-glucans is the main barrier to the penetration of antifungal drugs.

Aim:
This study aimed to study the mechanism of recombinant β-1,3-glucanase activity as an antibiofilm agent to increase the effectiveness of antifungals in treating vulvovaginitis candidiasis (VVC).

Methods:
Recombinant β-1,3-glucanase was produced using recombinant DNA technology and tested for its antibiofilm activity against C. albicans biofilms. Tests were carried out at the adhesion stage, biofilm formation, and mature biofilm using the crystal violet assay, scanning electron microscope (SEM), confocal laser scanning microscope (CLSM) methods, and cell viability tests. The combination of β-1,3-glucanase with fluconazole was also evaluated to measure its synergistic effect on biofilm matrix degradation and cell viability.

Results:
The results showed that recombinant β-1,3-glucanase affected all stages of C. albicans biofilm formation. Recombinant β-1,3-glucanase was able to inhibit biofilm matrix formation by 86.05% and reduce C. albicans cell viability by 75.43% when combined with fluconazole. SEM and CLSM analyses revealed significant damage to the 3D structure of the biofilm, demonstrating the synergistic effectiveness of the combination of the two agents. The combination of recombinant β-1,3-glucanase with fluconazole in vitro was shown to be effective in inhibiting biofilm formation and eradicating mature C. albicans biofilms.

Conclusion:
These findings indicate the great potential of β-1,3-glucanase to be applied as an antifungal concomitant agent for overcoming antimicrobial resistance in biofilm infections such as VVC. Further studies are needed to evaluate the effectiveness of the drug in in vivo models and clinical applications.

Key words: Antimicrobial resistance, C. albicans biofilm, Fluconazole, Recombinant β-1,3-glucanase, Vulvovaginitis candidiasis







Bibliomed Article Statistics

48
24
12
16
13
13
16
14
15
R
E
A
D
S

161

30

16

13

12

14

25

16

16
D
O
W
N
L
O
A
D
S
060708091011120102
20252026

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.